2020
Drápela, Stanislav; Khirsariya, Prashant; Weerden, Wytske M.; Fedr, Radek; Suchánková, Tereza; Búzová, Diana; Červený, Jan; Hampl, Aleš; Puhr, Martin; Watson, William R.; Culig, Zoran; Krejčí, Lumír; Paruch, Kamil; Souček, Karel
In: Molecular oncology, vol. 14, no. 10, pp. 2487–2503, 2020, ISSN: 1878-0261 1574-7891, (Place: United States).
Abstract | Links | BibTeX | Tags: *Mitosis/drug effects, Animals, castration-resistant prostate cancer, Cell Death/drug effects, Cell Line, Cell Proliferation/drug effects, Checkpoint Kinase 1, Checkpoint Kinase 1/*antagonists & inhibitors/metabolism, Deoxycytidine/*analogs & derivatives/pharmacology, Docetaxel resistance, Docetaxel/*pharmacology, Drug resistance, gemcitabine, Humans, Male, Mice, mitotic catastrophe, MU380, Neoplasm/*drug effects, Piperidines/chemistry/*pharmacology, Prostatic Neoplasms/*pathology, Pyrazoles/chemistry/*pharmacology, Pyrimidines/chemistry/*pharmacology, S Phase/drug effects, SCID, Tumor, Xenograft Model Antitumor Assays
@article{drapela_chk1_2020,
title = {The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.},
author = {Stanislav Drápela and Prashant Khirsariya and Wytske M. Weerden and Radek Fedr and Tereza Suchánková and Diana Búzová and Jan Červený and Aleš Hampl and Martin Puhr and William R. Watson and Zoran Culig and Lumír Krejčí and Kamil Paruch and Karel Souček},
doi = {10.1002/1878-0261.12756},
issn = {1878-0261 1574-7891},
year = {2020},
date = {2020-10-01},
journal = {Molecular oncology},
volume = {14},
number = {10},
pages = {2487–2503},
abstract = {As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naïve and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.},
note = {Place: United States},
keywords = {*Mitosis/drug effects, Animals, castration-resistant prostate cancer, Cell Death/drug effects, Cell Line, Cell Proliferation/drug effects, Checkpoint Kinase 1, Checkpoint Kinase 1/*antagonists & inhibitors/metabolism, Deoxycytidine/*analogs & derivatives/pharmacology, Docetaxel resistance, Docetaxel/*pharmacology, Drug resistance, gemcitabine, Humans, Male, Mice, mitotic catastrophe, MU380, Neoplasm/*drug effects, Piperidines/chemistry/*pharmacology, Prostatic Neoplasms/*pathology, Pyrazoles/chemistry/*pharmacology, Pyrimidines/chemistry/*pharmacology, S Phase/drug effects, SCID, Tumor, Xenograft Model Antitumor Assays},
pubstate = {published},
tppubtype = {article}
}
2015
Pálková, Lenka; Vondráček, Jan; Trilecová, Lenka; Ciganek, Miroslav; Pěnčíková, Kateřina; Neča, Jiří; Milcová, Alena; Topinka, Jan; Machala, Miroslav
In: Toxicology in vitro : an international journal published in association with BIBRA, vol. 29, no. 3, pp. 438–448, 2015, ISSN: 1879-3177 0887-2333, (Place: England).
Abstract | Links | BibTeX | Tags: Air Pollutants/*toxicity, Air pollution, Animals, Apoptosis, Apoptosis/drug effects, Aryl Hydrocarbon/*drug effects, Cell Cycle/drug effects, Cell Death/drug effects, Cell Proliferation, DNA adducts, DNA Damage, DNA damage response, Liver/*pathology, Lung/*pathology, Male, Mutagens/*toxicity, PAHs, Particulate Matter/*toxicity, Prostate/*pathology, Rats, Receptors, SRM 1650b, Vehicle Emissions/*toxicity
@article{palkova_aryl_2015,
title = {The aryl hydrocarbon receptor-mediated and genotoxic effects of fractionated extract of standard reference diesel exhaust particle material in pulmonary, liver and prostate cells.},
author = {Lenka Pálková and Jan Vondráček and Lenka Trilecová and Miroslav Ciganek and Kateřina Pěnčíková and Jiří Neča and Alena Milcová and Jan Topinka and Miroslav Machala},
doi = {10.1016/j.tiv.2014.12.002},
issn = {1879-3177 0887-2333},
year = {2015},
date = {2015-04-01},
journal = {Toxicology in vitro : an international journal published in association with BIBRA},
volume = {29},
number = {3},
pages = {438–448},
abstract = {Diesel exhaust particles (DEP) and the associated complex mixtures of organic pollutants, such as polycyclic aromatic hydrocarbons (PAHs), or their derivatives, have been suggested to exert deleterious effects on human health. We used a set of defined cellular models representing liver, lung and prostate tissues, in order to compare non-genotoxic and genotoxic effects of crude and fractionated extract of a standard reference DEP material - SRM 1650b. We focused on the aryl hydrocarbon receptor (AhR)-mediated activity, modulation of cell proliferation, formation of DNA adducts, oxidative DNA damage, and induction of DNA damage responses, including evaluation of apoptosis, and phosphorylation of p53 tumor suppressor and checkpoint kinases (Chk). Both PAHs and the polar aromatic compounds contributed to the AhR-mediated activity of DEP-associated organic pollutants. The principal identified AhR agonists included benzo[k]fluoranthene, indeno[1,2,3-c,d]pyrene, chrysene and several non-priority PAHs, including benzochrysenes and methylated PAHs. In contrast to PAHs, polar compounds contributed more significantly to overall formation of DNA adducts associated with phosphorylation of p53, Chk1 or Chk2, and partly with apoptosis. Therefore, more attention should be paid to identification of DEP-associated polar organic compounds, contributing to the AhR activation and cytotoxic/genotoxic effects of complex airborne mixtures of organic contaminants produced by diesel engines.},
note = {Place: England},
keywords = {Air Pollutants/*toxicity, Air pollution, Animals, Apoptosis, Apoptosis/drug effects, Aryl Hydrocarbon/*drug effects, Cell Cycle/drug effects, Cell Death/drug effects, Cell Proliferation, DNA adducts, DNA Damage, DNA damage response, Liver/*pathology, Lung/*pathology, Male, Mutagens/*toxicity, PAHs, Particulate Matter/*toxicity, Prostate/*pathology, Rats, Receptors, SRM 1650b, Vehicle Emissions/*toxicity},
pubstate = {published},
tppubtype = {article}
}
2006
Vondrácek, Jan; Svihálková-Sindlerová, Lenka; Pencíková, Katerina; Krcmár, Pavel; Andrysík, Zdenek; Chramostová, Katerina; Marvanová, Sona; Valovicová, Zuzana; Kozubík, Alois; Gábelová, Alena; Machala, Miroslav
In: Mutation research, vol. 596, no. 1-2, pp. 43–56, 2006, ISSN: 0027-5107, (Place: Netherlands).
Abstract | Links | BibTeX | Tags: Animals, Aryl Hydrocarbon Hydroxylases/genetics, Base Sequence, Carbazoles/*toxicity, Carcinogens/*toxicity, Cell Death/drug effects, Cytochrome P-450 CYP1A1/genetics, Cytochrome P-450 CYP1A2/genetics, Cytochrome P-450 CYP1B1, DNA Primers, Epithelial Cells/drug effects/*pathology, Inbred F344, Liver/*cytology/drug effects, Methylation, Molecular Structure, Mutagens, Rats, Reverse Transcriptase Polymerase Chain Reaction
@article{vondracek_7h-dibenzocgcarbazole_2006,
title = {7H-Dibenzo[c,g]carbazole and 5,9-dimethyldibenzo[c,g]carbazole exert multiple toxic events contributing to tumor promotion in rat liver epithelial 'stem-like' cells.},
author = {Jan Vondrácek and Lenka Svihálková-Sindlerová and Katerina Pencíková and Pavel Krcmár and Zdenek Andrysík and Katerina Chramostová and Sona Marvanová and Zuzana Valovicová and Alois Kozubík and Alena Gábelová and Miroslav Machala},
doi = {10.1016/j.mrfmmm.2005.11.005},
issn = {0027-5107},
year = {2006},
date = {2006-04-01},
journal = {Mutation research},
volume = {596},
number = {1-2},
pages = {43–56},
abstract = {Immature liver progenitor cells have been suggested to be an important target of hepatotoxins and hepatocarcinogens. The goal of the present study was to assess the impact of 7H-dibenzo[c,g]carbazole (DBC) and its tissue-specific carcinogenic N-methyl (N-MeDBC) and 5,9-dimethyl (DiMeDBC) derivatives on rat liver epithelial WB-F344 cells, in vitro model of liver progenitor cells. We investigated the cellular events associated with both tumor initiation and promotion, such as activation of aryl hydrocarbon receptor (AhR), changes in expression of enzymes involved in metabolic activation of DBC and its derivatives, effects on cell cycle, cell proliferation/apoptosis and inhibition of gap junctional intercellular communication (GJIC). N-MeDBC, a tissue-specific sarcomagen, was only a weak inhibitor of GJIC or inducer of AhR-mediated activity, and it did not affect either cell proliferation or apoptosis. DBC was efficient GJIC inhibitor, while DiMeDBC manifested the strongest AhR inducing activity. Accordingly, DiMeDBC was also the most potent inducer of cytochrome P450 1A1 (CYP1A1) and CYP1A2 expression among the three compounds tested. Both DBC and DiMeDBC induced expression of CYP1B1 and aldo-keto reductase 1C9 (AKR1C9). N-MeDBC failed to significantly upregulate CYP1A1/2 and it only moderately increased CYP1B1 or AKR1C9. Only the potent liver carcinogens, DBC and DiMeDBC, caused a significant increase of p53 phosphorylation at Ser15, an increased accumulation of cells in S-phase and apoptosis at micromolar concentrations. In addition, DiMeDBC was found to stimulate cell proliferation of contact-inhibited WB-F344 cells at 1 microM concentration, which is a mode of action that might further contribute to its hepatocarcinogenicity. The present data seem to suggest that the AhR activation, induction of enzymes involved in metabolic activation, inhibition of GJIC or stimulation of cell proliferation might all contribute to the hepatocarcinogenic effects of DBC and DiMeDBC.},
note = {Place: Netherlands},
keywords = {Animals, Aryl Hydrocarbon Hydroxylases/genetics, Base Sequence, Carbazoles/*toxicity, Carcinogens/*toxicity, Cell Death/drug effects, Cytochrome P-450 CYP1A1/genetics, Cytochrome P-450 CYP1A2/genetics, Cytochrome P-450 CYP1B1, DNA Primers, Epithelial Cells/drug effects/*pathology, Inbred F344, Liver/*cytology/drug effects, Methylation, Molecular Structure, Mutagens, Rats, Reverse Transcriptase Polymerase Chain Reaction},
pubstate = {published},
tppubtype = {article}
}
2002
Vaculová, Alena; Hofmanova, Jirina; Soucek, Karel; Kovariková, Martina; Kozubík, Alois
Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells. Journal Article
In: Anticancer research, vol. 22, no. 3, pp. 1635–1639, 2002, ISSN: 0250-7005, (Place: Greece).
Abstract | BibTeX | Tags: Apoptosis/*drug effects, Caspase 3, Caspases/metabolism, Cell Death/drug effects, Cell Division/drug effects, HT29 Cells/*drug effects/enzymology/pathology, Humans, Kinetics, Poly(ADP-ribose) Polymerases/*metabolism, Reactive Oxygen Species/metabolism, Tumor Necrosis Factor-alpha/*pharmacology
@article{vaculova_tumor_2002,
title = {Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells.},
author = {Alena Vaculová and Jirina Hofmanova and Karel Soucek and Martina Kovariková and Alois Kozubík},
issn = {0250-7005},
year = {2002},
date = {2002-06-01},
journal = {Anticancer research},
volume = {22},
number = {3},
pages = {1635–1639},
abstract = {BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is known for its selective cytotoxic activity on tumour cells. We analysed the response of HT-29 human colon carcinoma cells to this cytokine. MATERIALS AND METHODS: After TNF-alpha treatment, cell proliferation, cell cycle, reactive oxygen species (ROS) production (flow cytometry), the amount of apoptotic cells (flow cytometry, fluorescence microscopy), cleavage of poly (ADP-ribose) polymerase (PARP) and caspase-3 activity (Western blotting) were detected. RESULTS: TNF-alpha induced a decrease of cell growth and viability, an accumulation of cells in the S-phase of the cell cycle, an increase of subdiploid cell population and nuclear chromatin condensation and fragmentation, but not sooner than 96-120 hours. However, earlier events characteristic of apoptosis occurred, such as caspase-3 activation, PARP cleavage to 89 kDa fragment and changes in ROS production. CONCLUSION: We demonstrated that, in addition to being an early marker of apoptosis, activation of caspase-3 and degradation of PARP may play a causative role in HT-29 cell death induced by TNF-alpha.},
note = {Place: Greece},
keywords = {Apoptosis/*drug effects, Caspase 3, Caspases/metabolism, Cell Death/drug effects, Cell Division/drug effects, HT29 Cells/*drug effects/enzymology/pathology, Humans, Kinetics, Poly(ADP-ribose) Polymerases/*metabolism, Reactive Oxygen Species/metabolism, Tumor Necrosis Factor-alpha/*pharmacology},
pubstate = {published},
tppubtype = {article}
}